DNA Repair Process Inhibition (DDRi)

DNA repair process inhibition refers to the targeted disruption of cellular mechanisms responsible for detecting and repairing DNA damage. These processes are essential for maintaining genomic stability, and their inhibition is a key strategy in cancer therapy, as many tumors rely on specific DNA repair pathways to survive the high levels of genomic stress they experience. Inhibition involves targeting critical components within various DDR pathways using small molecule drugs—either alone or synergistically with traditional cytotoxic therapies—to maximize tumor cell death while minimizing harm to normal tissues.

Other names

DNA Damage Response InhibitionDDR Inhibition

Small molecule inhibitors block key proteins involved in DNA repair pathways, preventing the repair of DNA damage and leading to cell death. Inhibition can target specific enzymes such as PARP, DNA-PK, CHK1/CHK2, or Pol beta, disrupting processes like single-strand break repair, NHEJ, cell cycle checkpoints, or BER respectively.